CN107952111A - A kind of bone cement containing cooling agent and preparation method - Google Patents
A kind of bone cement containing cooling agent and preparation method Download PDFInfo
- Publication number
- CN107952111A CN107952111A CN201711210073.3A CN201711210073A CN107952111A CN 107952111 A CN107952111 A CN 107952111A CN 201711210073 A CN201711210073 A CN 201711210073A CN 107952111 A CN107952111 A CN 107952111A
- Authority
- CN
- China
- Prior art keywords
- bone cement
- liquid
- cooling agent
- powder
- silver
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002639 bone cement Substances 0.000 title claims abstract description 93
- 239000002826 coolant Substances 0.000 title claims abstract description 27
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 239000007788 liquid Substances 0.000 claims abstract description 57
- 239000000843 powder Substances 0.000 claims abstract description 35
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 claims abstract description 32
- 229920003229 poly(methyl methacrylate) Polymers 0.000 claims abstract description 15
- 239000004926 polymethyl methacrylate Substances 0.000 claims abstract description 15
- 238000006243 chemical reaction Methods 0.000 claims abstract description 12
- 239000004342 Benzoyl peroxide Substances 0.000 claims abstract description 11
- 235000019400 benzoyl peroxide Nutrition 0.000 claims abstract description 11
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229920000058 polyacrylate Polymers 0.000 claims abstract description 8
- 238000002156 mixing Methods 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims abstract description 4
- 239000011777 magnesium Substances 0.000 claims description 44
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 34
- 229910052749 magnesium Inorganic materials 0.000 claims description 34
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 claims description 26
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 claims description 20
- DHEQXMRUPNDRPG-UHFFFAOYSA-N strontium nitrate Chemical compound [Sr+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O DHEQXMRUPNDRPG-UHFFFAOYSA-N 0.000 claims description 20
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims description 17
- 239000002244 precipitate Substances 0.000 claims description 15
- YIXJRHPUWRPCBB-UHFFFAOYSA-N magnesium nitrate Chemical compound [Mg+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O YIXJRHPUWRPCBB-UHFFFAOYSA-N 0.000 claims description 14
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims description 13
- 229910001961 silver nitrate Inorganic materials 0.000 claims description 10
- VWDWKYIASSYTQR-YTBWXGASSA-N sodium;dioxido(oxo)azanium Chemical compound [Na+].[O-][15N+]([O-])=O VWDWKYIASSYTQR-YTBWXGASSA-N 0.000 claims description 10
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims description 8
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 claims description 8
- 235000012661 lycopene Nutrition 0.000 claims description 8
- 239000001751 lycopene Substances 0.000 claims description 8
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 claims description 8
- 229960004999 lycopene Drugs 0.000 claims description 8
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 claims description 8
- 230000008439 repair process Effects 0.000 claims description 7
- 230000004888 barrier function Effects 0.000 claims description 6
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 5
- 239000000908 ammonium hydroxide Substances 0.000 claims description 5
- 238000004140 cleaning Methods 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 5
- 239000000839 emulsion Substances 0.000 claims description 5
- 238000000227 grinding Methods 0.000 claims description 5
- 238000007654 immersion Methods 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 238000001556 precipitation Methods 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 3
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 claims description 3
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 2
- 239000011812 mixed powder Substances 0.000 claims description 2
- 229910052586 apatite Inorganic materials 0.000 abstract description 15
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 abstract description 15
- 238000007711 solidification Methods 0.000 abstract description 8
- 230000008023 solidification Effects 0.000 abstract description 8
- 210000000988 bone and bone Anatomy 0.000 abstract description 7
- 238000010521 absorption reaction Methods 0.000 abstract description 3
- 230000002138 osteoinductive effect Effects 0.000 abstract description 3
- 230000008569 process Effects 0.000 abstract description 3
- 238000009825 accumulation Methods 0.000 abstract description 2
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 2
- 230000007547 defect Effects 0.000 abstract description 2
- 238000011049 filling Methods 0.000 abstract description 2
- SYJBLFMEUQWNFD-UHFFFAOYSA-N magnesium strontium Chemical compound [Mg].[Sr] SYJBLFMEUQWNFD-UHFFFAOYSA-N 0.000 abstract description 2
- 125000004185 ester group Chemical group 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 32
- 239000003795 chemical substances by application Substances 0.000 description 8
- 229910052712 strontium Inorganic materials 0.000 description 8
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 7
- 238000010348 incorporation Methods 0.000 description 7
- 229910052709 silver Inorganic materials 0.000 description 7
- 239000004332 silver Substances 0.000 description 7
- 230000006835 compression Effects 0.000 description 5
- 238000007906 compression Methods 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000005070 sampling Methods 0.000 description 4
- CHIHQLCVLOXUJW-UHFFFAOYSA-N benzoic anhydride Chemical compound C=1C=CC=CC=1C(=O)OC(=O)C1=CC=CC=C1 CHIHQLCVLOXUJW-UHFFFAOYSA-N 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- 208000010392 Bone Fractures Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- AGEYGQSGMUPBSY-UHFFFAOYSA-N [P].[Sr].[Mg] Chemical compound [P].[Sr].[Mg] AGEYGQSGMUPBSY-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 150000002148 esters Chemical group 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000004575 stone Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 235000019738 Limestone Nutrition 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 238000001027 hydrothermal synthesis Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000006028 limestone Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/16—Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/025—Other specific inorganic materials not covered by A61L27/04 - A61L27/12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/12—Phosphorus-containing materials, e.g. apatite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/58—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
- A61L2300/104—Silver, e.g. silver sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/112—Phosphorus-containing compounds, e.g. phosphates, phosphonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/402—Anaestetics, analgesics, e.g. lidocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
- A61L2300/604—Biodegradation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/06—Flowable or injectable implant compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Materials For Medical Uses (AREA)
Abstract
The present invention relates to a kind of bone cement containing cooling agent and preparation method, bone cement to be mainly made of powder and liquid, and wherein powder contains benzoyl peroxide, silver-colored strontium magnesium apatite, polyacrylate, barium sulfate etc., and liquid contains cooling agent.By powder and liquid according to powder liquid mass ratio 1~2.5:1 mixing, is made the bone cement.Cooling agent is introduced in bone cement liquid, with methymethacrylate the Ester exchange endothermic reaction occurs for cooling agent in bone cement solidification process, it is grafted on PMMA strands, due to heat absorption, the heat of MMA polymerisations release is reduced, reduces the maximum temperature of bone cement, and since the addition of cooling agent extends the hardening time of bone cement, the concentration accumulation of heat is further reduced, reduces bone cement maximum temperature.Bone cement produced by the present invention has the characteristics that antibacterial, syringeability are good, while also has good biocompatibility and osteoinductive, can be used for the fixation of a variety of fracture and the filling reparation of bone defect.
Description
Technical field
The present invention relates to a kind of bone cement containing cooling agent and preparation method, belong to bone material field.
Background technology
Polyacrylate bone cement is that it is by powder and liquid two parts at present clinically using a kind of most bone cements
Composition.Powder main component is polymethyl methacrylate, and liquid main component is methyl methacrylate monomer.Bone cement can
Arbitrary shape is injection moulded and is made, mechanical strength is high, but bone cement also having some limitations property at the same time, as monomer has necessarily
Toxicity, developer nonabsorable, biocompatibility be not good enough, cannot absorb degraded after injecting human body, while it is without osteogenic action,
It is insecure with synosteosis, easily loosen, and the exothermic reaction in polymerization process may cause nervous function damage etc..
Studies have reported that the curing exotherm of bone cement is reduced by adding modifying agent in bone cement, such as
CN1810300A, a kind of micropore bone cement, is mixed by the raw material of following parts by weight：1 part of bone cement, modifying agent 0.2-0.7
Part；Wherein, the modifying agent is mixed by 30 parts by weight of modifying agent solid and water：1 part of modifying agent solid, water 0.5-
0.9 part；The modifying agent solid mixes 30-50 parts of binder by the binder, accelerating agent and pore former of parts by weight, promotes
30-50 parts of agent, 10-30 parts of pore former.The solidification temperature of bone cement separately is reduced by adding beta carotene in bone cement, such as
CN105031738A, in bone cement powder and liquid, introduces Hu Luoka elements respectively, when bone cement cures, part Hu Luoka elements
Decomposed under the action of BPO and be transformed into vitamin A, vitamin A occurs vinegar exchange reaction with MMA and absorbs heat, and extends consolidating for bone cement
Change the time, improve the injection property of bone cement, significantly reduce the heat release of bone cement.
The present invention in bone cement liquid by introducing cooling agent, cooling agent and methacrylic acid in bone cement solidification process
The Ester exchange endothermic reaction occurs for formicester, is grafted on PMMA strands, due to heat absorption, reduces the heat that MMA polymerisations discharge
Amount, and cooling agent is only introduced in bone cement liquid, optimize bone cement preparation process, and three elements are introduced in bone cement powder
Full substituted apatite.
Apatite is the material composition of the inanimate matter of human body hard tissue (bone and tooth), its chemical composition and crystal structure and ridge
The mineralogical composition of Vertebrate bone is very close, and doping apatite is to adulterate the displaced type formed after trace element in apatite to consolidate
Solution, according to the literature, its biological degradability and biocompatibility can be improved by mixing saamite, or even can be to a certain degree
Upper its bone-inducting active of raising, its biocidal property can be increased by mixing silver-colored apatite, its bioactivity etc. can be increased by mixing magnesium apatite.
Although having much to the preparation research for adulterating apatite, the research to multi-element doping apatite is less, and particularly three elements are complete
The research of substituted apatite has no report.
The present invention uses hydro-thermal method, controls product to precipitate by pH value, and control the temperature, pressure, time of reaction to prepare
Silver-colored magnesium saamite, and by its with polyacrylate, barium sulfate etc. are compound prepares bone cement powder, and draw in bone cement liquid
Enter cooling agent, reduce the polymerization temperature of bone cement, reduce injury of the bone cement curing exotherm to body, and three elements substitute phosphorus entirely
The addition of lime stone improves bioactivity, biocidal property and the osteoinductive of bone cement, and the research to related content of the present invention does not appear in the newspapers
Road.
The content of the invention
It is an object of the invention to provide a kind of new bone cement containing cooling agent and preparation method, draw in bone cement powder
Enter the silver-colored full substituted apatite of strontium magnesium, and introduce cooling agent in a liquid, reduce the solidification temperature of bone cement, extend the behaviour of bone cement
Make the time, obtained bone cement has the characteristics that antibiotic property, injectable, intensity are suitable, while also has good bio-compatible
Property and osteoinductive.
Bone cement forms and mass percentage is：
Powder：
Polyacrylate 40%~70%；
Barium sulfate 5%~20%；
Silver-colored magnesium saamite 10~50%；
Benzoyl peroxide 1%~5%；
Liquid：
N, N dimethyl para-totuidine 0.5%~5%；
Hydroquinone 0.05%~2%；
Methyl methacrylate 93~98.5%；
Cooling agent 0.5%~2%.
Polyacrylate can be homopolymer, copolymer or polymer, preferably polymethyl methacrylate.
Cooling agent can be one kind of lycopene, Ubiquinone-50.
Silver-colored magnesium saamite is the doping apatite that silver, magnesium, three element of strontium substitute entirely, using strontium element as base, magnesium, silver element
Codope, Ag/ (Ag+Mg+Sr) molar ratio are 1~10:100, Mg/ (Ag+Mg+Sr) molar ratios are 1~30:100, Sr/ (Ag+
Mg+Sr) molar ratio is 60~98:100, (Ag+Mg+Sr)/P molar ratio are 100:60.
The preparation method of bone cement is：
(1) strontium nitrate, magnesium nitrate, silver nitrate solution and the ammonium dibasic phosphate solution of same concentrations, the concentration of solution are configured
For 0.05~0.2mol/L；
(2) four kinds of solution are pumped into reaction vessel at the same time, it is respectively 60~98mL/ of strontium nitrate solution to be pumped into speed
Min, 1~30mL/min of magnesium nitrate solution, 1~10mL/min of silver nitrate solution, ammonium dibasic phosphate solution 60mL/min, four kinds molten
Liquid terminates to be pumped at the same time, and it is 10~30min to be pumped into the time, obtains white emulsion, continues to be uniformly mixed；
(3) ammonium hydroxide is added, has white precipitate gradually to separate out, adjustment pH value is 10~12, continues to be uniformly mixed；
(4) white precipitate is separated from liquid, white precipitate is transferred in the barrier box containing micron openings, control isolation
For box on liquid upper strata, liquid just immersion precipitation, is 150~250 DEG C in temperature, pressure reacts 4 under conditions of being 0.4~2MPa
~24h, cleaning, drying, last 500~1000 DEG C, sinter 3~12h, cooling, grinding obtain 5~200 μm of silver-colored magnesium strontium phosphorus ash
Stone.
(5) silver-colored magnesium saamite is uniformly mixed with polyacrylate, benzoyl peroxide, barium sulfate, obtains bone cement
Powder, by N, N dimethyl para-totuidine, hydroquinone, methyl methacrylate, cooling agent are uniformly mixed, and obtain bone cement liquid
Body；
(6) according to powder liquid mass ratio 1~2.5:1 is uniformly mixed powder and liquid, is expelled to required position and completes to repair.
Continue to be uniformly mixed described in above-mentioned steps (2), (3), preferably incorporation time is 5~60min.
The advantage of the invention is that：Introduce cooling agent in bone cement liquid, cooling agent and first in bone cement solidification process
The Ester exchange endothermic reaction occurs for base methacrylate, is grafted on PMMA strands, due to heat absorption, reduces MMA polymerisations
The heat of release, reduces the maximum temperature of bone cement, and since the addition of cooling agent extends the hardening time of bone cement, more
The concentration accumulation of heat is reduce further, reduces bone cement maximum temperature.And introducing, there is antibiotic property, bioactivity and bone to lure
The full substituted apatite of three elements for the property led.
Calcium constituent is all replaced with strontium, magnesium, silver element in the preparation process of apatite, is formed using strontium element as base, magnesium,
The problem of silver-colored magnesium saamite of silver element doping, solves using calcium constituent as base, the more difficult doping of the element of larger ionic radius,
Strontium, silver element ionic radius are big, and magnesium elements ionic radius is small, and using strontium element as base, silver, magnesium elements easily lift doping content, make
The apatite of standby highly doped amount.Silver-colored magnesium saamite and polyacrylate be compound to prepare bone cement, the addition of silver-colored magnesium saamite,
Since strontium has partial development effect, the use of barium sulfate developer is reduced, improves the biocompatibility and biology of bone cement
Activity, silver-colored magnesium saamite discharge a variety of needed by human body trace elements at the same time, and silver sustained release degraded assigns bone cement good antibacterial
Effect, obvious bacteriostasis is respectively provided with to Gram-negative bacteria and gram-positive bacteria；The sustained release degraded of strontium improves bone water
Biocompatibility, the bone-inducting active of mud, the sustained release degraded of magnesium improve bone density and anti-brittleness, reduce bone-loss and fracture
Incidence, and play the role of analgesic, alleviate the psychological pressure of patient.The filling of fixation, bone defect available for a variety of fracture.
Brief description of the drawings
Fig. 1：Bone cement solidification temperature curve comparison figure；
Fig. 2：The compression strength figure of the bone cement containing cooling agent.
Embodiment
Present disclosure is described in further detail with reference to embodiment, but embodiments of the present invention are unlimited
In this.
Bone cement and preparation method are as follows：
(1) strontium nitrate, magnesium nitrate, silver nitrate solution and the ammonium dibasic phosphate solution of 0.05~0.2mol/L is configured,
(2) four kinds of solution are pumped into reaction vessel at the same time, it is respectively 60~98mL/ of strontium nitrate solution to be pumped into speed
Min, 1~30mL/min of magnesium nitrate solution, 1~10mL/min of silver nitrate solution, ammonium dibasic phosphate solution 60mL/min, four kinds molten
Liquid terminates to be pumped at the same time, and it is 10~30min to be pumped into the time, obtains white emulsion, continues to be uniformly mixed, incorporation time for 5~
60min；
(3) ammonium hydroxide is added, has white precipitate gradually to separate out, adjustment pH value is 10~12, continues to be uniformly mixed, incorporation time
For 5~60min；
(4) white precipitate is separated from liquid, white precipitate is transferred in the barrier box containing micron openings, control isolation
For box on liquid upper strata, liquid just immersion precipitation, is 150~250 DEG C in temperature, pressure reacts 4 under conditions of being 0.4~2MPa
~24h, cleaning, drying, last 500~1000 DEG C, sinter 3~12h, cooling, grinding obtain 5~200 μm of silver-colored magnesium strontium phosphorus ash
Stone.
(5) by 10~50% silver-colored magnesium saamite and 40%~70% polymethyl methacrylate, 1%~5%
Benzoyl peroxide, 5%~20% barium sulfate are uniformly mixed, and obtain bone cement powder, by 0.5%~5% N, N dimethyl
Para-totuidine, 0.05%~2% hydroquinone, 93~98.5% methyl methacrylate, 0.5%~2% cooling agent
It is uniformly mixed, obtains bone cement liquid；
(6) according to powder liquid mass ratio 1~2.5:1, bone cement powder is added in bone cement liquid and is uniformly mixed, there is 4
The injection time of~10min, is expelled to required position and completes to repair.
Embodiment 1
Powder contains 70% polymethyl methacrylate, 18% barium sulfate, 10% silver-colored magnesium saamite, 2% mistake
Benzoyl Oxide；Liquid contains 2% N, N dimethyl para-totuidine, 1% hydroquinone, 1% lycopene, 96%
Methyl methacrylate.
Bone cement preparation method is as follows：
(1) strontium nitrate, magnesium nitrate, silver nitrate solution and the ammonium dibasic phosphate solution of 0.05mol/L is configured,
(2) four kinds of solution are pumped into reaction vessel at the same time, it is respectively strontium nitrate solution 98mL/min to be pumped into speed, nitre
Sour magnesium solution 1mL/min, silver nitrate solution 1mL/min, ammonium dibasic phosphate solution 60mL/min, four kinds of solution terminate to pump at the same time
Enter, it is 10min to be pumped into the time, obtains white emulsion, continues to be uniformly mixed, incorporation time 60min；
(3) ammonium hydroxide is added, has white precipitate gradually to separate out, adjustment pH value is 10, continues to be uniformly mixed, incorporation time is
5min；
(4) white precipitate is separated from liquid, white precipitate is transferred in the barrier box containing micron openings, control isolation
For box on liquid upper strata, liquid just immersion precipitation, is 150 DEG C in temperature, and pressure reacts 8h under conditions of being 1.35MPa, cleaning,
It is dry, last 500 DEG C, 12h is sintered, cooling, grinding obtain 5~200 μm of silver-colored magnesium saamite.
(5) by 10% silver-colored magnesium saamite and 70% polymethyl methacrylate, 2% benzoyl peroxide,
18% barium sulfate is uniformly mixed, and obtains bone cement powder, by 2% N, N dimethyl para-totuidine, and 1% hydroquinone,
1% lycopene, 97% methyl methacrylate are uniformly mixed, and obtain bone cement liquid；
(6) according to powder liquid mass ratio 2.5:1 by bone cement powder be added in bone cement liquid be uniformly mixed, have 8min's
Injection time, is expelled to required position and completes to repair.
According to the solidification temperature of the requirement test bone cement of YY0459 standards, test curve is as shown in Fig. 1-b, maximum temperature
For 65.4 DEG C, it is 15.5min that maximum temperature, which corresponds to the time, shown in Fig. 1-a, to be 91 DEG C without cooling agent maximum temperature, and highest
It is 10.8min that temperature, which corresponds to the time,.
Bone cement is expelled in sampling die, the sample that a diameter of 6.0mm length is 12mm is obtained after curing.Omnipotent
Intensity test is carried out on mechanics tester, as shown in attached drawing 2-D, obtained sample compression strength is 79.1MPa.
Embodiment 2
Powder contains 40% polymethyl methacrylate, 8% barium sulfate, 50% silver-colored magnesium saamite, 2% peroxide
Change benzoyl；Liquid contains 2% N, N dimethyl para-totuidine, 1% hydroquinone, 1% Ubiquinone-50,96% methyl
Methyl acrylate.
Bone cement preparation method is as follows：
(1) saamite prepared using embodiment 1；
(2) by 50% silver-colored magnesium saamite and 40% polymethyl methacrylate, 2% benzoyl peroxide, 8%
Barium sulfate be uniformly mixed, obtain bone cement powder, by 2% N, N dimethyl para-totuidine, 1% hydroquinone, 1%
Ubiquinone-50,97% methyl methacrylate are uniformly mixed, and obtain bone cement liquid；
(3) according to powder liquid mass ratio 2.5:1 by bone cement powder be added in bone cement liquid be uniformly mixed, have 6min's
Injection time, is expelled to required position and completes to repair.
According to YY0459 standards requirement test bone cement solidification temperature, test curve as shown in fig 1-c, maximum temperature
For 69.5 DEG C, it is 13min that maximum temperature, which corresponds to the time,.
Bone cement is expelled in sampling die, the sample that a diameter of 6.0mm length is 12mm is obtained after curing.Omnipotent
Intensity test is carried out on mechanics tester, as shown in attached drawing 2-E, obtained sample compression strength is 75.3MPa.
Embodiment 3
Powder contains 60% polymethyl methacrylate, 10% barium sulfate, 28% silver-colored magnesium saamite, 2% mistake
Benzoyl Oxide；Liquid contains 4% N, N dimethyl para-totuidine, 1% hydroquinone, 2% lycopene, 93%
Methyl methacrylate.
Bone cement preparation method is as follows：
(1) strontium nitrate, magnesium nitrate, silver nitrate solution and the ammonium dibasic phosphate solution of 0.2mol/L is configured,
(2) four kinds of solution are pumped into reaction vessel at the same time, it is respectively strontium nitrate solution 89mL/min to be pumped into speed, nitre
Sour magnesium solution 10mL/min, silver nitrate solution 1mL/min, ammonium dibasic phosphate solution 60mL/min, four kinds of solution terminate to pump at the same time
Enter, it is 30min to be pumped into the time, obtains white emulsion, continues to be uniformly mixed, incorporation time 5min；
(3) ammonium hydroxide is added, has white precipitate gradually to separate out, adjustment pH value is 12, continues to be uniformly mixed, incorporation time is
60min；
(4) white precipitate is separated from liquid, white precipitate is transferred in the barrier box containing micron openings, control isolation
For box on liquid upper strata, liquid just immersion precipitation, is 200 DEG C in temperature, and pressure reacts 12h under conditions of being 1.5MPa, cleaning,
It is dry, last 1000 DEG C, 4h is sintered, cooling, grinding obtain 5~200 μm of silver-colored magnesium saamite.
(5) by 28% silver-colored magnesium saamite and 60% polymethyl methacrylate, 2% benzoyl peroxide,
10% barium sulfate is uniformly mixed, and obtains bone cement powder, by 4% N, N dimethyl para-totuidine, and 1% hydroquinone,
2% lycopene, 93% methyl methacrylate are uniformly mixed, and obtain bone cement liquid；
(6) according to powder liquid mass ratio 2:Bone cement powder is added in bone cement liquid and is uniformly mixed by 1, there is the note of 9min
The time is penetrated, required position is expelled to and completes to repair.
Bone cement is expelled in sampling die, the sample that a diameter of 6.0mm length is 12mm is obtained after curing.Omnipotent
Intensity test is carried out on mechanics tester, as shown in attached drawing 2-F, obtained sample compression strength is 72.2MPa.
Embodiment 4
Powder contains 70% polymethyl methacrylate, 14% barium sulfate, 15% silver-colored magnesium saamite, 1% mistake
Benzoyl Oxide；Liquid contains 3% N, N dimethyl para-totuidine, 1% hydroquinone, 0.5% lycopene,
95.5% methyl methacrylate.
Bone cement preparation method is as follows：
(1) saamite prepared using embodiment 3；
(2) by 15% silver-colored magnesium saamite and 70% polymethyl methacrylate, 1% benzoyl peroxide,
14% barium sulfate is uniformly mixed, and obtains bone cement powder, by 3% N, N dimethyl para-totuidine, and 1% hydroquinone,
0.5% lycopene, 95.5% methyl methacrylate are uniformly mixed, and obtain bone cement liquid；
(3) according to powder liquid mass ratio 2:Bone cement powder is added in bone cement liquid and is uniformly mixed by 1, there is the note of 6min
The time is penetrated, required position is expelled to and completes to repair.
Bone cement is expelled in sampling die, the sample that a diameter of 6.0mm length is 12mm is obtained after curing.Omnipotent
Intensity test is carried out on mechanics tester, as shown in attached drawing 2-G, obtained sample compression strength is 82.8MPa.
Claims (5)
1. a kind of bone cement containing cooling agent, it is characterised in that composition and mass percentage are：
Powder：
Polymethyl methacrylate 40%~70%；
Barium sulfate 5%~20%；
Silver-colored magnesium saamite 10~50%；
Benzoyl peroxide 1%~5%；
Liquid：
N, N dimethyl para-totuidine 0.5%~5%；
Hydroquinone 0.05%~2%；
Methyl methacrylate 93~98.5%；
Cooling agent 0.5%~2%.
2. bone cement as claimed in claim 1, it is characterised in that cooling agent is one kind of lycopene or Ubiquinone-50.
3. bone cement as claimed in claim 1, it is characterised in that in silver-colored magnesium saamite, Ag/ (Ag+Mg+Sr) molar ratio is
1~10:100, Mg/ (Ag+Mg+Sr) molar ratios are 1~30:100, Sr/ (Ag+Mg+Sr) molar ratios are 60~98:100, (Ag+
Mg+Sr)/P molar ratios are 100:60.
4. the preparation method of bone cement as claimed in claim 1, it is characterised in that step is as follows：
(1) silver nitrate, magnesium nitrate, strontium nitrate solution and the ammonium dibasic phosphate solution of same concentrations are configured, the concentration of solution is
0.05~0.2mol/L；
(2) four kinds of solution are pumped into reaction vessel at the same time, it is respectively 60~98mL/min of strontium nitrate solution to be pumped into speed, nitre
Sour 1~30mL/min of magnesium solution, 1~10mL/min of silver nitrate solution, ammonium dibasic phosphate solution 60mL/min, four kinds of solution are at the same time
End is pumped into, and it is 10~30min to be pumped into the time, obtains white emulsion, continues to be uniformly mixed；
(3) ammonium hydroxide is added, has white precipitate gradually to separate out, adjustment pH value is 10~12, continues to be uniformly mixed；
(4) white precipitate is separated from liquid, white precipitate is transferred in the barrier box containing micron openings, control barrier box exists
Liquid upper strata, liquid just immersion precipitation, is 150~250 DEG C in temperature, reaction 4 under conditions of pressure is 0.4~2MPa~
24h, cleaning, drying, last 500~1000 DEG C, sinter 3~12h, cooling, grinding obtain 5~200 μm of silver-colored magnesium saamite.
(5) silver-colored magnesium saamite is uniformly mixed with polyacrylate, benzoyl peroxide, barium sulfate, obtains bone cement powder,
By N, N dimethyl para-totuidine, hydroquinone, methyl methacrylate, cooling agent are uniformly mixed, and obtain bone cement liquid；
(6) according to powder liquid mass ratio 1~2.5:1 is uniformly mixed powder and liquid, is expelled to required position and completes to repair.
5. method as claimed in claim 4, it is characterised in that continue to be uniformly mixed described in step (2), (3), during mixing
Between be 5~60min.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711210073.3A CN107952111A (en) | 2017-11-27 | 2017-11-27 | A kind of bone cement containing cooling agent and preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711210073.3A CN107952111A (en) | 2017-11-27 | 2017-11-27 | A kind of bone cement containing cooling agent and preparation method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107952111A true CN107952111A (en) | 2018-04-24 |
Family
ID=61962254
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711210073.3A Pending CN107952111A (en) | 2017-11-27 | 2017-11-27 | A kind of bone cement containing cooling agent and preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107952111A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109091701A (en) * | 2018-09-27 | 2018-12-28 | 中国科学院上海硅酸盐研究所 | A kind of organic bone cement of low temperature and preparation method thereof |
| CN109316627A (en) * | 2018-10-26 | 2019-02-12 | 中国医学科学院北京协和医院 | A kind of novel artificial bone material and its preparation method and application |
| CN109331226A (en) * | 2018-10-26 | 2019-02-15 | 中国医学科学院北京协和医院 | A kind of modified mineralized collagen artificial bone and its preparation method and application |
| CN111905150A (en) * | 2020-08-10 | 2020-11-10 | 中国人民解放军总医院第一医学中心 | Bone cement with color development function |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105031738A (en) * | 2015-09-09 | 2015-11-11 | 山东明德生物医学工程有限公司 | Weak-exothermic bone cement and preparation method and application |
| CN105107021A (en) * | 2015-09-09 | 2015-12-02 | 天津大学 | Injectable antibacterial bone cement and preparation method and application thereof |
| CN105439110A (en) * | 2015-11-12 | 2016-03-30 | 中国科学院金属研究所 | Sr and Mg doped amorphous apatite material and crystalline apatite material |
| CN106075587A (en) * | 2016-06-07 | 2016-11-09 | 山东明德生物医学工程有限公司 | Polynary codope bone cement and preparation method |
-
2017
- 2017-11-27 CN CN201711210073.3A patent/CN107952111A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105031738A (en) * | 2015-09-09 | 2015-11-11 | 山东明德生物医学工程有限公司 | Weak-exothermic bone cement and preparation method and application |
| CN105107021A (en) * | 2015-09-09 | 2015-12-02 | 天津大学 | Injectable antibacterial bone cement and preparation method and application thereof |
| CN105439110A (en) * | 2015-11-12 | 2016-03-30 | 中国科学院金属研究所 | Sr and Mg doped amorphous apatite material and crystalline apatite material |
| CN106075587A (en) * | 2016-06-07 | 2016-11-09 | 山东明德生物医学工程有限公司 | Polynary codope bone cement and preparation method |
Non-Patent Citations (2)
| Title |
|---|
| 林英光: "溶胶-凝胶结合超临界流体干燥法制备纳米掺锶羟基磷灰石的研究", 《高校化学工程学报》 * |
| 薛淼: "《口腔生物材料学》", 30 September 2006, 上海世界图书出版公司 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109091701A (en) * | 2018-09-27 | 2018-12-28 | 中国科学院上海硅酸盐研究所 | A kind of organic bone cement of low temperature and preparation method thereof |
| CN109316627A (en) * | 2018-10-26 | 2019-02-12 | 中国医学科学院北京协和医院 | A kind of novel artificial bone material and its preparation method and application |
| CN109331226A (en) * | 2018-10-26 | 2019-02-15 | 中国医学科学院北京协和医院 | A kind of modified mineralized collagen artificial bone and its preparation method and application |
| CN111905150A (en) * | 2020-08-10 | 2020-11-10 | 中国人民解放军总医院第一医学中心 | Bone cement with color development function |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107952111A (en) | A kind of bone cement containing cooling agent and preparation method | |
| CN100345598C (en) | Implant comprising calcium cement and hydrophobic liquid | |
| CN108635624B (en) | Anti-collapsibility injectable magnesium phosphate-based bone cement | |
| CN1323726C (en) | Strontium-apatite-cement-preparations, cements formed therefrom, and uses thereof | |
| CN105120908B (en) | The improved solidification of hardenable bone substitute | |
| CN1481343A (en) | Biocompatible cement contg reactive calcium phosphate nanoparticles and methods for making and using such cement | |
| CN105107021A (en) | Injectable antibacterial bone cement and preparation method and application thereof | |
| CN1923302A (en) | Calcium sulfate semihydrate group combined self-curing bio-active material, preparation and application thereof | |
| CN107185033A (en) | A kind of anti-infection bio ceramic artificial bone and its application | |
| CN104591679B (en) | A kind of modified chloromagnesia bone cement and its preparation method and application | |
| CN106075587B (en) | Multi-element co-doped bone cement and preparation method thereof | |
| JPS6242625B2 (en) | ||
| CN104147639A (en) | Injectable bone cement containing strontium and preparation method of bone cement | |
| CN107982576A (en) | A kind of bone cement and preparation method | |
| CN105031738B (en) | A kind of low heat release bone cement and preparation method and application | |
| JP2002331026A (en) | Orthopaedic filling material and method for using the same | |
| CN106139253B (en) | The bone cement that the composition of composite bone cement can be formed and formed by it | |
| Sha et al. | A modified calcium silicate composite bone cement prepared from polyethylene glycol and graphene oxide for biomaterials | |
| CN103830774B (en) | A kind of bone cement and preparation method thereof | |
| CN105536059B (en) | A kind of selfreparing injecting bone cement and preparation method | |
| CN106620843A (en) | Composite bone cement with bioactivity and antibacterial activity as well as preparation method and application | |
| CN101428152A (en) | Composite self-curing material of dicalcium silicate, preparation and uses thereof | |
| CN110339395B (en) | PMMA-based hydrated bone cement and preparation method and application thereof | |
| CN102249728B (en) | Biological porous bone cement prepared by compositing Sr-doped calcium-phosphorus bioglass and alpha-tricalcium phosphate and preparation method thereof | |
| JP6414949B2 (en) | Self-curing chitosan-containing calcium phosphate composition, kit for producing the composition, and production method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180424 |
|
| RJ01 | Rejection of invention patent application after publication |